Tavarua

Cidara Therapeutics Presents Promising New Data on Novel Drug-Fc Conjugate Candidates at the American Association for Cancer Research (AACR) Annual Meeting 2024

Retrieved on: 
Friday, April 5, 2024
CDTX, Colorectal cancer, Drug, Adenosine, Patient, SAN, Tavarua, AACR, Therapy, Cancer, Pathology, CCR5, CD73, DFC, San Diego Convention Center, Oleclumab, Escape Room, Vaccine

SAN DIEGO, April 05, 2024 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) immunotherapies designed to save lives and improve the standard of care for patients facing serious diseases, announced the company will deliver four poster presentations, including one late-breaking poster presentation, at this year’s American Association for Cancer Research (AACR) Annual Meeting being held April 5-10, 2024 at the San Diego Convention Center in San Diego, California. The presentations highlight data on the company’s multispecific CD73/PD-1 drug Fc-conjugate (DFC), its CCR5-targeting DFC, and CBO421, its lead oncology DFC candidate targeting CD73.

Key Points: 
  • The presentations highlight data on the company’s multispecific CD73/PD-1 drug Fc-conjugate (DFC), its CCR5-targeting DFC, and CBO421, its lead oncology DFC candidate targeting CD73.
  • “Our Cloudbreak platform has quickly produced DFC candidates effective in preclinical studies across various cancers with specific disease targets.
  • This week, we are sharing data on our CCR5 DFC program for the first time, which has demonstrated robust efficacy as a monotherapy in mouse models of colorectal cancer.
  • Targeting CCR5 has the potential to improve response rates to immune checkpoint inhibitor therapies, which could have a greater impact for patients unresponsive to these current treatment options.

New Survey Results from Cloudbreak Pharma Highlight Disease Burden, Need for Non-surgical Treatment Options for Underdiagnosed and Undertreated Ocular Disease

Retrieved on: 
Friday, April 5, 2024
Health, Clinical Trials, Research, Science, Pharmaceutical, Optical, Biotechnology, Diagnosis, Pterygium, Disease, Eye, Conjunctiva, Safety, Physician, ASCRS, Air conditioning, Conjunctivitis, Tavarua, Tearing, Contact, Dry, Volunteering, Wind, Efficacy, Ophthalmology, Pollen, Chronic, Irritation, Pharmacokinetics, Vision, HCP, Recurrence, Pharma, Food

“Simple tasks like putting in contact lenses, applying makeup and using a computer or phone are made significantly more difficult, if not impossible, for those with pterygium.

Key Points: 
  • “Simple tasks like putting in contact lenses, applying makeup and using a computer or phone are made significantly more difficult, if not impossible, for those with pterygium.
  • As ophthalmologists, we need to listen closely to our patients and coordinate with optometrists to fully understand the impact of pterygium.
  • More information about this trial is available here: Safety and Efficacy of CBT-001 Ophthalmic Solution in Patients With Pterygium .
  • The survey was designed with multiple-choice questions, rating questions and open-ended questions.2

Cidara Therapeutics Receives $11.14 Million Milestone Payment Following European Approval of REZZAYO

Retrieved on: 
Monday, February 12, 2024
SAN, European Commission, Committee, CDTX, Tavarua, Caspofungin, FDA, Standard of care, Fungemia, Civil service commission, Therapy, CHMP, Patient, DFC, IND, Immune system, CD73, Pharmaceutical industry

SAN DIEGO, Feb. 12, 2024 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) immunotherapies designed to save lives and improve the standard of care for patients facing serious diseases, today announced receipt of an $11.14 million milestone payment from Mundipharma following the European approval of REZZAYO™ (rezafungin acetate), a novel, once-weekly echinocandin antifungal approved for the treatment of invasive candidiasis in adults.

Key Points: 
  • SAN DIEGO, Feb. 12, 2024 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) immunotherapies designed to save lives and improve the standard of care for patients facing serious diseases, today announced receipt of an $11.14 million milestone payment from Mundipharma following the European approval of REZZAYO™ (rezafungin acetate), a novel, once-weekly echinocandin antifungal approved for the treatment of invasive candidiasis in adults.
  • The drug was previously approved by the United States Food and Drug Administration (FDA) for the treatment of candidemia and invasive candidiasis in patients with limited or no treatment options.
  • “The European approval of REZZAYO marks a significant milestone for patients who are in need of new treatment options for invasive candidiasis, and we look forward to seeing Mundipharma bring it to the EU market,” said Jeffrey Stein, Ph.D., president and chief executive officer of Cidara.
  • Its lead oncology DFC, CBO421, is a potential best-in-class inhibitor of CD73, a validated target highly expressed on tumor cells.

Element to Present Data on New Products and Multi-Omics Capabilities at AGBT

Retrieved on: 
Monday, February 5, 2024
ABC, Tavarua, SAN, Workflow, Multi, RNA, Science, Research, Agriculture, DNA, Mass meeting, Gene, Biomedicine, Systems biology, Informatics, SVP, UC, Protein, Computational biology, HD, Learning, Biomedical engineering, Cancer, Endothelium, Doctor of Philosophy, Element, Q50, Leukemia

Never before have so many data points been available to researchers at this cost and speed.

Key Points: 
  • Never before have so many data points been available to researchers at this cost and speed.
  • Cloudbreak UltraQ is the industry's first commercial Q50 kit capable of generating 100-fold higher accuracy than currently available published specifications.
  • Trinity is Element's on-board enrichment solution that simplifies targeted sequencing, to provide users with a new level of convenience, flexibility, and performance.
  • AVITI24 streamlines these studies and data collection to enable rapid recursive learning with broad applications across systems biology.

Element Announces Expanded Customer Base, New Products, and Unprecedented Capabilities on a Benchtop Sequencer

Retrieved on: 
Tuesday, January 9, 2024
Biology, RNA, Associate, JPM, Conference, Science, Protein, Wellcome Sanger Institute, Research, Pathology, CRISPR, DNA, Doctor of Philosophy, SAN, HD, Stanford University, Genetics, Computational biology, Trinity, Genome, Cell biology, Q50, Biological engineering, Tavarua, Pharmaceutical industry

Achieving the fastest growth rate since launch among its peers, Element generated revenues in excess of $25 million in 2023.

Key Points: 
  • Achieving the fastest growth rate since launch among its peers, Element generated revenues in excess of $25 million in 2023.
  • Element CEO and Co-founder Molly He presented on the following updates to AVITI at JPM:
    Expert mode HD – Enhanced output options.
  • An instrument option that allows users to generate 20 to 70 percent more reads per run from all sequencing kits.
  • "When we launched AVITI in 2022 we redefined what is possible on a benchtop sequencer, offering an unprecedented combination of accuracy, speed, and cost.

UpHealth Enters into Definitive Agreement for Sale of Cloudbreak Health Business to GTCR for $180 Million

Retrieved on: 
Thursday, November 16, 2023
Sale, IV District, Turku, NYSE, DLA Piper, Tablet, Patient, UPH, Growth, GTCR, Tavarua

DELRAY BEACH, Fla., Nov. 16, 2023 (GLOBE NEWSWIRE) -- UpHealth, Inc. (“UpHealth,” the “Company”) (NYSE: UPH), today announced that it has entered into a definitive agreement to sell its wholly-owned subsidiary Cloudbreak Health, LLC (“Cloudbreak”), best known for its Martti translation offering, to GTCR for $180 million in cash. GTCR is a leading private equity firm that partners with management leaders to identify, acquire and build market-leading companies through organic growth and strategic acquisitions.

Key Points: 
  • UpHealth Will Focus on TTC Healthcare, A Growing, Cash Flow Positive Behavioral Health Business
    DELRAY BEACH, Fla., Nov. 16, 2023 (GLOBE NEWSWIRE) -- UpHealth, Inc. (“UpHealth,” the “Company”) (NYSE: UPH), today announced that it has entered into a definitive agreement to sell its wholly-owned subsidiary Cloudbreak Health, LLC (“Cloudbreak”), best known for its Martti translation offering, to GTCR for $180 million in cash.
  • GTCR is a leading private equity firm that partners with management leaders to identify, acquire and build market-leading companies through organic growth and strategic acquisitions.
  • UpHealth will utilize the proceeds from the sale for payment in full or in part of the Company’s 2026 Unsecured and 2025 Secured Notes, as well as other expenses related to the transaction.
  • As part of the transaction, GTCR will acquire complete equity ownership of Cloudbreak, including the aggregate Cloudbreak employee base.

GTCR to Acquire Cloudbreak Health

Retrieved on: 
Thursday, November 16, 2023
Health equity, NYSE, Entrepreneurship, Barings LLC, LLP, Patient satisfaction, Kirkland & Ellis, Investment, Patient, Telecommunications, Caregiver, Health, UPH, Hospital, GTCR, Tavarua

CHICAGO, Nov. 16, 2023 /PRNewswire/ -- GTCR, a leading private equity firm, announced today that it has signed a definitive agreement to acquire Cloudbreak Health, LLC ("Cloudbreak" or "the Company"), a leading provider of tech-enabled, healthcare-focused language interpretation services, in a corporate carve-out transaction from UpHealth, Inc. ("UpHealth", NYSE: UPH). Under the terms of the agreement, the purchase price is $180 million, and the transaction is expected to close in the first quarter of 2024 following the receipt of customary regulatory and stockholder approvals and closing conditions.

Key Points: 
  • CHICAGO, Nov. 16, 2023 /PRNewswire/ -- GTCR, a leading private equity firm, announced today that it has signed a definitive agreement to acquire Cloudbreak Health, LLC ("Cloudbreak" or "the Company"), a leading provider of tech-enabled, healthcare-focused language interpretation services, in a corporate carve-out transaction from UpHealth, Inc. ("UpHealth", NYSE: UPH).
  • Cloudbreak serves clinicians and patients across all types of healthcare settings, including hospitals, urgent care centers, standalone clinics and medical practices and helps improve health equity across an underserved U.S. patient population.
  • GTCR has substantial experience in the healthcare technology segment in which Cloudbreak operates.
  • "We are excited to partner with Cloudbreak and its talented team to drive this market leading business forward," added Geoffrey Tresley, Principal at GTCR.

Cidara Therapeutics Provides Corporate Update and Reports Third Quarter 2023 Financial Results

Retrieved on: 
Thursday, November 2, 2023
Research, Medicare, Influenza, Treatment, European Directive on Traditional Herbal Medicinal Products, New Drug Application, Centers for Medicare & Medicaid Services, Fungal infection, Translation, DFC, CHMP, Committee for Medicinal Products for Human Use, CDTX, European Medicines Agency, Invasive candidiasis, EMA, Safety, CD73, Therapy, Patient, European Commission, ATM, Respect, Committee, Conference, NTAP, New Shrimadhopur DFC Station, Janssen Pharmaceuticals, Tavarua, FDA, IND, EC, Senior, Johnson & Johnson, CMS, SAN, Pharmaceutical industry, Vaccine, Cryptocurrency, Security (finance), Janssen, Mundipharma, Melinta Therapeutics

Nicole is a practicing oncology physician and joins us from Genentech/Roche where she has had substantial cancer-focused product development experience.

Key Points: 
  • Nicole is a practicing oncology physician and joins us from Genentech/Roche where she has had substantial cancer-focused product development experience.
  • Presented at IDWeek 2023: In September 2023, Cidara delivered an oral presentation and two poster presentations highlighting the safety and efficacy of CD388.
  • For the nine months ended September 30, 2023 and 2022, net loss was $17.3 million and $16.4 million, respectively.
  • During the three months ended September 30, 2023, Cidara did not sell shares of common stock pursuant to its at-the-market (ATM) sales agreement.

Cidara Therapeutics and Mundipharma receive positive CHMP opinion for rezafungin for the treatment of Invasive Candidiasis in adults(1)

Retrieved on: 
Friday, October 13, 2023
European, Infection, Restore, Committee for Medicinal Products for Human Use, CHMP, Fungal infection, European Medicines Agency, DFC, CDTX, Mortality, European Commission, Tavarua, Safety, Disease, EMA, Medical Mycology, FDA, Therapy, Phase, EC, Mycology, Committee, Immune system, SAN, News, Candidiasis, Civil service commission, Caspofungin, Patient, Medical device, Pharmaceutical industry, Vaccine, Mundipharma

A new treatment option for these serious infections is a much-needed addition.”

Key Points: 
  • A new treatment option for these serious infections is a much-needed addition.”
    “We would like to thank the CHMP for their careful consideration of the use of rezafungin.
  • This positive opinion represents an important step on the journey towards approval and brings us closer to providing clinicians with an alternative treatment option for invasive Candida infections, giving hope to patients battling this infection and their families,” said Brian Sheehan, Ph.D., Chief Scientific Officer at Mundipharma.
  • The CHMP’s positive opinion on rezafungin for the treatment of serious fungal infections, such as invasive candidiasis in adults, will be referred to the European Commission (EC), which will deliver a final decision in approximately two months.
  • Cidara Therapeutics has partnered with Mundipharma, which has commercial rights to rezafungin outside the U.S. and Japan.

Cidara Therapeutics Presents New Preclinical and Clinical Data on Novel Drug-Fc Conjugate CD388 at IDWeek 2023

Retrieved on: 
Wednesday, October 11, 2023
Pharmacokinetics, DFC, SCID, Universal, CDTX, Janssen, Johnson & Johnson, Tavarua, Safety, Drug, Boston Convention and Exhibition Center, Therapy, Doctor of Philosophy, SAN, Janssen Pharmaceuticals, Convention center, Intramuscular injection, Patient, Pharmaceutical industry, Vaccine

SAN DIEGO, Oct. 11, 2023 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) therapies designed to save lives and improve the standard of care for patients facing serious diseases, today announced new data on its drug-Fc conjugate (DFC) candidate, CD388, at IDWeek 2023.

Key Points: 
  • SAN DIEGO, Oct. 11, 2023 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) therapies designed to save lives and improve the standard of care for patients facing serious diseases, today announced new data on its drug-Fc conjugate (DFC) candidate, CD388, at IDWeek 2023.
  • The conference is taking place both in-person at the Boston Convention and Exhibition Center in Boston, MA and virtually from October 11 – 15, 2023.
  • “It is important to highlight these new data demonstrating the safety, efficacy and tolerability of CD388 in preventing influenza A and B,” said Jeffrey Stein, Ph.D. president and chief executive officer of Cidara.
  • Janssen recently delivered its Election to Proceed Notice for CD388 with the intent to transfer its rights and obligations to another entity.